The protective effect of obesity on mortality among those with (or without) CVD cannot be fully explained by collider-stratification bias.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Protective effect of intensive glucose lowering therapy on all-cause mortality, adjusted for treatment switching using G-estimation method, the ACCORD trial.Scientific reports · 2023
   Trial
2. Association between obesity and statin use on mortality and hospital encounters in atrial fibrillation.International journal of cardiology. Heart & vasculature · 2024
   Article
3. Longitudinal effects of lipid indices on incident cardiovascular diseases adjusting for time-varying confounding using marginal structural models: 25 years follow-up of two US cohort studies.Global epidemiology · 2022
   Article

Corrections and comments

• Comment on
  Association of body mass index with life expectancy with and without cardiovascular disease.2020
• Comment on
  Selection bias can creep into unselected cohorts and produce counterintuitive findings.2021

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as